Last checked at 
LONDON (Alliance News) - Biotechnology firm Allergy Therapeutics PLC on Monday said it has received positive new data in a study investigating its microcrystalline tyrosine-based vaccines.
The results, it said, show MCT is a "suitable and flexible" alternative to aluminium hydroxide in both allergen-specific immunotherapy and infectious disease applications.
Further, they also showed the MCT-adjuvanted allergens caused fewer anaphylactic reactions compared to alum-adjuvanted allergens.
International Medical Director Matthias Kramer said: "These findings provide evidence of the effectiveness of MCT as an adjuvant, confirming the mechanism of action underlying its ability to induce a robust and sustained immunological response. Additionally, the findings indicated a potentially favourable profile for the use of MCT over alum in allergy-specific vaccines."
"We believe these data highlight the significance of our differentiated proprietary platform technology in the development of our growing suite of cutting-edge, globally marketed ultra-short course allergy vaccines."
Shares were up 3.2% on Monday at a price of 24.50 pence each.
